Items Tagged ‘pegilodecakin’

April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study


CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment